Vernalis plc - Product Pipeline Review - 2012 - This pharmaceuticals report, "Vernalis plc - Product Pipeline Review - 2012" provides data on the Vernalis plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Vernalis plc's corporate website, SEC filings, investor presentations and featured press releases, both from Vernalis plc and industry-specific third party sources, put together by This team.
Scope
- Vernalis plc - Brief Vernalis plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Vernalis plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Vernalis plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Vernalis plc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Vernalis plc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Vernalis plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vernalis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vernalis plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vernalis plc and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Vernalis plc; Vernalis plc - Key Therapeutics; Vernalis plc - Pipeline Overview and Promising Molecules; Vernalis plc - News; Vernalis plc - Latest Updates; Vernalis plc - Pipeline; Vernalis plc - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
Vernalis plc Snapshot
Vernalis plc Overview
Key Information
Key Facts
Vernalis plc - Research and Development Overview
Key Therapeutic Areas
Vernalis plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Vernalis plc - Pipeline Products Glance
Vernalis plc Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Vernalis plc - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Vernalis plc - Drug Profiles
V158411
Product Description
Mechanism of Action
R&D Progress
V158866
Product Description
Mechanism of Action
R&D Progress
V81444
Product Description
Mechanism of Action
R&D Progress
V85546
Product Description
Mechanism of Action
R&D Progress
Vernalis plc - Pipeline Analysis
Vernalis plc - Pipeline Products by Therapeutic Class
Vernalis plc - Pipeline Products by Route of Administration
Vernalis plc - Pipeline Products By Mechanism of Action
Vernalis plc - Recent Pipeline Updates
Vernalis plc - Dormant Projects
Vernalis plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BB-2827
BB-3644
V10153
V140
V24343
V3881
VML 670
Vernalis plc - Company Statement
Vernalis plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Vernalis plc, Recent Developments
Vernalis plc- Press Release
Aug 13, 2012: Vernalis To Present Positive Phase I Results Of V158866 At 14th World Congress On Pain
May 02, 2012: Vernalis Reports Positive Results From Phase I Study Of V81444 To Treat Parkinson's Disease
Oct 06, 2009: Vernalis Initiates Pilot Study Of V3381 In Patients With Chronic Cough
Sep 15, 2009: Vernalis Completes Recruitment In V3381 Phase II IN-STEP Study For Neuropathic Pain
Jul 21, 2009: Vernalis Plc Announces New Oncology Development Candidate V158411
Financial Deals Landscape
Vernalis plc, Deals Summary
Vernalis plc, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Vernalis Acquires Frovatriptan Royalties From Paul Capital Healthcare
Partnerships
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier
H. Lundbeck Enters Into Collaboration With Vernalis
Vernalis Expands Its Collaboration Agreement With Les Laboratoires Servier
Vernalis Enters Into Research Agreement With GlaxoSmithKline
Les Laboratoires Servier Enters Into An Agreement With Vernalis
Licensing Agreements
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products
Vernalis Enters Into Licensing Agreement With Servier
Equity Offering
Vernalis Completes Private Placement Of Ordinary Shares For $31 Million
Vernalis Completes Public Offering Of Ordinary Shares For $77.7 Million
Vernalis Completes Offering Of Ordinary Shares For $46.9 Million
Asset Transactions
Ipsen Acquires Apokyn and US Commercial Operations From Vernalis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Vernalis plc, Key Information
Vernalis plc, Key Facts
Vernalis plc - Pipeline by Indication, 2012
Vernalis plc - Pipeline by Stage of Development, 2012
Vernalis plc - Monotherapy Products in Pipeline, 2012
Vernalis plc - Phase I, 2012
Vernalis plc - Pre-Clinical, 2012
Vernalis plc - Pipeline By Therapeutic Class, 2012
Vernalis plc - Pipeline By Route of Administration, 2012
Vernalis plc - Pipeline Products By Mechanism of Action, 2012
Vernalis plc - Recent Pipeline Updates, 2012
Vernalis plc - Dormant Developmental Projects,2012
Vernalis plc - Discontinued Pipeline Products, 2012
Vernalis plc, Subsidiaries
Vernalis plc, Deals Summary
Vernalis Acquires Frovatriptan Royalties From Paul Capital Healthcare
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier
H. Lundbeck Enters Into Collaboration With Vernalis
Vernalis Expands Its Collaboration Agreement With Les Laboratoires Servier
Vernalis Enters Into Research Agreement With GlaxoSmithKline
Les Laboratoires Servier Enters Into An Agreement With Vernalis
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products
Vernalis Enters Into Licensing Agreement With Servier
Vernalis Completes Private Placement Of Ordinary Shares For $31 Million
Vernalis Completes Public Offering Of Ordinary Shares For $77.7 Million
Vernalis Completes Offering Of Ordinary Shares For $46.9 Million
Ipsen Acquires Apokyn and US Commercial Operations From Vernalis
List of Figures
Vernalis plc - Pipeline by Indication, 2012
Vernalis plc - Pipeline by Stage of Development, 2012
Vernalis plc - Monotherapy Products in Pipeline, 2012
Vernalis plc - Pipeline By Therapeutic Class, 2012
Vernalis plc - Pipeline Products By Mechanism of Action, 2012 19